Peptide research, regulation, discovery. Every story links to the peptide it’s about.
RSSThe FDA's compounding advisory committee closed a two-day peptide session Friday by recommending Semax (8 to 5) and Epitalon (7 to 4), then rejecting Emideltide, or DSIP, 6 to 7. It was the only no vote across seven peptides. Six now head toward a rulemaking that could take up to 18 months, every one of them over the objection of the FDA's own scientists.
After BPC-157 and KPV, the compounding committee voted 8-6 for TB-500 and 7-5 for MOTS-c. Both are banned in sport. Neither has ever been tested in a person.
The Pharmacy Compounding Advisory Committee recommended adding BPC-157 and KPV to the 503A bulks list, overruling FDA career scientists who said neither peptide had human safety or efficacy data. The vote is a recommendation, not a final rule.
Novo Nordisk sued Eli Lilly over 'false and materially misleading' weight-loss ads, and the case turns on Lilly stacking its top tirzepatide dose against an older, lower dose of semaglutide.
Providers at LifeMD, a telehealth company Novo Nordisk lists as a legitimate GLP-1 source, were at times expected to clear 25 patient cases an hour, about two minutes each, five former employees and two lawsuits say.
In nearly a million people with type 2 diabetes, SGLT2 inhibitors were tied to fewer osteoarthritis diagnoses than GLP-1 drugs. The edge vanished at the endpoint that counts, knee and hip replacement.
DMS-DA6, a dermaseptin from the Mexican leaf frog, cleared actinomycetoma in mice on eight injections while linezolid took about fifty-six doses. It killed bacteria and retuned the immune response at once.
Samsung Biologics, known for making antibodies, offered 1.8 billion dollars for Swiss peptide maker PolyPeptide. The bet is that injectable GLP-1 demand keeps growing even as oral pills arrive.
Temporin-GHaR6R, an antimicrobial peptide from frog skin, cut how often mice developed an MS-like disease when given before onset. It worked by steering brain immune cells out of their inflammatory state and fusing their fragmented mitochondria back together.
In eight pooled studies of heart-attack patients, adding a GLP-1 drug shrank the patch of dead heart muscle by about 10 points relative to the muscle at risk. The infarct result rests on just three small trials, and liraglutide carried most of the pump-function gain.
Alpha-1 antitrypsin ran higher in bacterial community-acquired pneumonia than viral, independent of CRP, with an AUC of 0.803. Its shed C-terminal peptides split further: C37 leaned bacterial, C40 leaned viral.
Pep19-2.5, built to soak up bacterial toxins, turns out to shut down the NLRP3 inflammasome from inside the cell. In mouse airways it cut IL-1 beta and eosinophils and improved lung function.
Intranasal vasopressin lowered voluntary ethanol intake in mice without moving blood pressure. Blocking any one of three receptors it lands on (V1a, V1b, or the oxytocin receptor) undid the effect, and social housing recruited a different receptor than solitary housing.
In veterans with diabetes and opioid use disorder, semaglutide and tirzepatide beat insulin and SGLT2 inhibitors on 12-month overdose risk but tied metformin, sulfonylureas, and DPP-4 drugs. The verdict flips with the comparator.
The first registered review of GLP-1 receptor agonists in multiple sclerosis found the drugs reliably reduced disease severity in mice but trimmed only weight in patients, with no change in disability or relapse across barely a hundred people.